Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, December 19, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Life Technologies Corporation (NASDAQ:LIFE), OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), Halozyme Therapeutics, Inc. (NASDAQ:HALO), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), and PTC Therapeutics, Inc. (NASDAQ:PTCT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Life Technologies Corporation Research Report
On December 10, 2013, Life Technologies Corporation (Life Technologies) announced that the Company has expanded their GeneArt® Algae Engineering portfolio. According to the Company, the new kits contain features requested by algae biologists and are designed to make work with algae simpler and faster. Additionally, the Company stated that the GeneArt® Chlamydomonas Protein Expression Kits and GeneArt® Synechoccus Protein Expression Kits contain high-expression vectors capable of driving production of genes of interest to as much 10% of total cellular protein. Commenting on the release, Nathan Wood, General Manager and Vice President of Synthetic Biology for Life Technologies, stated, "By combining high levels of both DNA transformation and protein expression, the new GeneArt® kits allow investigators to move beyond basic research into more of a production mode and applied science. These were features specifically requested by users of our first generation kits, and we believe these capabilities will help algae biologists advance their field to level of ease that typifies work with yeast and E. coli." The Full Research Report on Life Technologies Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
OncoMed Pharmaceuticals, Inc. Research Report
On December 16, 2013, OncoMed Pharmaceuticals, Inc.'s stock climbed up 21.11% and closed the day at $28.91 per share. The Company's stock increased by as much as 23.02% over the past three trading days compared to the Nasdaq composite which went up by 0.64% during the same three day trading period. The Full Research Report on OncoMed Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Halozyme Therapeutics, Inc. Research Report
On December 16, 2013, Halozyme Therapeutics, Inc.'s stock went down by 0.15%, closing the day at $13.08 per share. However, the Company's stock reflected an increase of 2.27% over the past three-day trading period, compared to the Dow Jones Industrial Average which went up by 0.26% during the same three-day trading period. The Full Research Report on Halozyme Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Infinity Pharmaceuticals, Inc. Research Report
On December 16, 2013, Infinity Pharmaceuticals, Inc.'s stock went down by 1.77%, closing the day at $12.73 per share. For the past three trading days, the Company's stock went down by 4.36%, compared to the Dow Jones Industrial Average which went up by 0.26% over the same three-day trading period. The Full Research Report on Infinity Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
PTC Therapeutics, Inc. Research Report
On December 12, 2013, PTC Therapeutics, Inc. (PTC Therapeutics) announced the publication of data in PLOS ONE demonstrating that nonsense mutation Duchenne muscular dystrophy (nmDMD) patients treated with ataluren experienced an increase in dystrophin expression. According to the Company, patients with nmDMD typically experience decreased levels of dystrophin protein, which is critical to normal muscle function. Commenting on the release, Stuart Peltz, Ph.D., CEO of PTC Therapeutics, stated, "The results of this Phase 2a study support ataluren's activity as a dystrophin restoration therapy in nonsense mutation Duchenne muscular dystrophy patients mediated by ribosomal read-through of nonsense mutations. These positive findings were the basis for the progression into a Phase 2b study of ataluren in patients with nmDMD, which further demonstrated the potential of ataluren to slow the progression of nonsense mutation DMD as measured by the 6-Minute Walk Test and informed the design of our ongoing Phase 3 study to confirm the safety and efficacy of ataluren." The Full Research Report on PTC Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner